Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection

Phase 4 Completed 300 enrolled Baqiyatallah Medical Sciences University Baqiyatallah Research Center for Gastroenterology and Liver Diseases · collab Guilan University of Medical Sciences · collab Tabriz Research Center for Gastroenterology and Liver Diseases · collab Tehran Hepatitis Center · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Antiviral treatment of HCV in thalassemia has raised concerns of ribavirin-induced hemolysis and increased iron loading. Blood Transfusion in Thalassemic patients are a known high risk for acquiring hepatitis C. The investigators are trying the PEGASYS (Peginterferon alpha-2a(40 KD)) plus Ribavirin in Thalassemic patients with HCV.

Timeline

Start: 2007-05
Primary completion: 2009-09
Completion: 2009-09

Publications

Background Harmatz P, Jonas MM, Kwiatkowski JL, Wright EC, Fischer R, Vichinsky E, Giardina PJ, Neufeld EJ, Porter J, Olivieri N; Thalassemia Clinical Research Network. Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica. 2008 Aug;93(8):1247-51. doi: 10.3324/haematol.12352. Epub 2008 Jun 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Peginterferon Alfa-2a (40KD)	Unknown	180 ug	Other
Subject	Ribavirin	Small molecule	1000 mg	Oral
Subject	Ribavirin	Small molecule	1200 mg	Oral

Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection

Summary

Timeline

Publications

Drugs

Indications